OrganiGram Competitors

OrganiGram (NASDAQ:OGI) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. 3.7% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Xencor's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Xencor's gross revenue, earnings per share (EPS) and valuation.

Xencor has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Xencor, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Xencor has a consensus target price of $47.1111, indicating a potential upside of 6.61%. Given Xencor's stronger consensus rating and higher probable upside, analysts clearly believe Xencor is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Summary

Xencor beats OrganiGram on 10 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Global Blood Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Global Blood Therapeutics' gross revenue, earnings per share (EPS) and valuation.

OrganiGram has higher revenue and earnings than Global Blood Therapeutics. OrganiGram is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Global Blood Therapeutics, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Global Blood Therapeutics has a consensus target price of $93.8235, indicating a potential upside of 132.58%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Global Blood Therapeutics is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Summary

OrganiGram beats Global Blood Therapeutics on 8 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Deciphera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

OrganiGram has higher revenue and earnings than Deciphera Pharmaceuticals. OrganiGram is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Deciphera Pharmaceuticals has a consensus target price of $69.4444, indicating a potential upside of 61.65%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Summary

Deciphera Pharmaceuticals beats OrganiGram on 8 of the 14 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Axsome Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Axsome Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Axsome Therapeutics has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Axsome Therapeutics, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 121.87%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.

Summary

Axsome Therapeutics beats OrganiGram on 8 of the 13 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Prelude Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Prelude Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Prelude Therapeutics has lower revenue, but higher earnings than OrganiGram.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Prelude Therapeutics, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Prelude Therapeutics has a consensus target price of $41.3333, indicating a potential downside of 25.93%. Given OrganiGram's stronger consensus rating and higher probable upside, analysts clearly believe OrganiGram is more favorable than Prelude Therapeutics.

OrganiGram (NASDAQ:OGI) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Arcus Biosciences' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OrganiGram and Arcus Biosciences' gross revenue, earnings per share (EPS) and valuation.

Arcus Biosciences has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for OrganiGram and Arcus Biosciences, as reported by MarketBeat.com.

OrganiGram currently has a consensus target price of $2.93, indicating a potential upside of 3.90%. Arcus Biosciences has a consensus target price of $49.9091, indicating a potential upside of 49.47%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than OrganiGram.

Volatility & Risk

OrganiGram has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Summary

Arcus Biosciences beats OrganiGram on 9 of the 14 factors compared between the two stocks.